uniQure (NASDAQ:QURE) Director Sells $225,408.15 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 5,295 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $42.57, for a total transaction of $225,408.15. Following the transaction, the director owned 25,996 shares of the company’s stock, valued at approximately $1,106,649.72. This trade represents a 16.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Price Performance

NASDAQ:QURE opened at $48.85 on Thursday. The stock has a 50 day moving average of $26.59 and a two-hundred day moving average of $22.65. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market cap of $3.08 billion, a P/E ratio of -14.04 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc raised its stake in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after purchasing an additional 738,897 shares during the period. Quinn Opportunity Partners LLC acquired a new position in uniQure in the 3rd quarter valued at about $6,281,000. Farallon Capital Management LLC boosted its holdings in uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after purchasing an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
• Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
• Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
• Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title

Analyst Ratings Changes

Several equities research analysts have issued reports on QURE shares. Chardan Capital lifted their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada raised their price target on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Leerink Partners increased their price objective on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $58.92.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.